kristoff@GENBANK.BIO.NET (Dave Kristofferson) (02/23/90)
NIH GUIDE - Vol. 19, No. 7, February 16, 1990
NOTICES
GRANTEE REQUIREMENTS WHEN DESCRIBING PROJECTS OR PROGRAMS FUNDED WITH
FEDERAL MONEY ...........................................(84/119)............ 1
Public Health Service
Index: PUBLIC HEALTH SERVICE
DATED ANNOUNCEMENTS (RFPs AND RFAs)
THROMBOCYTOPENIC PURPURA IN HIV INFECTIONS (RFA 90-HL-07-B) ..(125/174)...... 1
National Heart, Lung, and Blood Institute (1204/1742)
Index: HEART, LUNG, BLOOD
GENETIC AND METABOLIC FACTORS IN OBESITY (RFA 90-HD/DK-05) ..(177/322)....... 2
National Institute of Child Health and Human Development (1745/2053)
National Institute of Diabetes and Digestive and Kidney Diseases
Index: CHILD HEALTH, HUMAN DEVELOPMENT, DIABETES, DIGESTIVE
DISEASES, KIDNEY DISEASES
NEW APPROACHES TO UNDERSTANDING TRANSFORMATION BY SV40 VIRUS,
POLYOMAVIRUSES AND ADENOVIRUSES (RFA 90-CA-09) ...(325/445, 2056/2397)....... 4
National Cancer Institute
Index: CANCER
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTION PROJECTS (RFA OD-90-01) ......... 5
National Institutes of Health (448/567, 2400/2961)
Index: NATIONAL INSTITUTES OF HEALTH
CONSTRUCTION OF A MOUSE PRODUCTION FACILITY (RFA OD-90-02) ..(570/673)....... 7
National Institutes of Health (2964/3514)
Index: NATIONAL INSTITUTES OF HEALTH
ONGOING PROGRAM ANNOUNCEMENTS
SMALL GRANTS PROGRAM ........................................(679/912)....... 8
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, BLOOD
NINTH ANNOUNCEMENT - TRANSFUSION MEDICINE ACADEMIC AWARD ....(915/993).......11
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, BLOOD
COMPREHENSIVE PREVENTION RESEARCH IN DRUG ABUSE .............(996/1191)......12
National Institute on Drug Abuse
Index: DRUG ABUSE
NOTICES
GRANTEE REQUIREMENTS WHEN DESCRIBING PROJECTS OR PROGRAMS FUNDED WITH FEDERAL
MONEY
P.T. 34; K.W. 1014002, 1014006
Public Health Service
The purpose of this notice is to advise grantees about a requirement set forth
in Section 511 of the Appropriations Act of the Department of Health and Human
Services for fiscal year 1990 (Public Law 101-166). Specifically, Section 511
reads as follows:
"When issuing statements, press releases, requests for proposals, bid
solicitations and other documents describing projects or programs funded in
whole or in part with Federal money, all grantees receiving Federal funds,
including but not limited to State and local governments, shall clearly state
(1) the percentage of the total costs of the program or project which will be
financed with Federal money, (2) the dollar amount of Federal funds for the
project or program, and (3) the percentage and dollar amount of the total
costs of the project or program that will be financed by non-governmental
sources."
All recipients of Public Health Service (PHS) grants and cooperative
agreements involving fiscal year 1990 appropriated funds must comply with the
requirements of Section 511.
This provision is similar to the government-wide requirements of the "Stevens
Amendment" contained in the Department of Defense Appropriations Act for
fiscal year 1989, as published in the NIH GUIDE FOR GRANTS AND CONTRACTS, Vol.
18, No. 11, March 31, 1989.
Because this is the second consecutive fiscal year for this legislative
provision, PHS has determined that the requirement for notice will remain in
effect until December 8, 1994, unless rescinded at an earlier date, as
prescribed in PHS Grants Administration Manual Circular 89.03, dated December
8, 1989.
DATED ANNOUNCEMENTS (RFPs AND RFAs)
THROMBOCYTOPENIC PURPURA IN HIV INFECTION
RFA AVAILABLE: 90-HL-07-B
P.T. 34, FF, II; K.W. 0715008, 0785070, 0710070, 1003018, 1002004
National Heart, Lung, and Blood Institute
Application Receipt Date: September 14, 1990
The Blood Diseases Branch of the Division of Blood Diseases and Resources,
National Heart, Lung, and Blood Institute (NHLBI), announces the availability
of a Request for Applications (RFA) on the above subject. Copies of the RFA
are currently available from staff of the NHLBI. Awards to foreign
institutions will be made only for research of very unusual merit, need, and
promise.
This special program will support research on the pathophysiology of
thrombocytopenias such as immune thrombocytopenic purpura and thrombotic
thrombocytopenic purpura in persons infected with Human Immunodeficiency
Virus. Information generated from this research will be utilized to develop
new and more effective therapy of thrombocytopenias. This announcement may be
of particular interest to investigators with expertise in hematology,
immunology, platelet biochemistry, cell biology and retroviral infection.
The support mechanism for this five-year program will be the traditional,
individual research grant. Although approximately $1,200,000 (for direct plus
indirect costs) for this program is included in the financial plans for fiscal
year 1991, award of grants pursuant to this RFA is contingent upon receipt of
funds for this purpose. The specific number of awards to be funded depends on
the merit and scope of the applications received and the availability of
funds.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 1
Women and minority individuals should be included in the study population;
otherwise a clear rationale for their exclusion must be provided in the
application. Minority institutions are encouraged to apply, and other
institutions are encouraged to establish collaborative arrangements with
minority institutions.
Requests for copies of the RFA may be addressed to:
Dr. Pankaj Ganguly
Division of Blood Diseases and Resources
National Heart, Lung and Blood Institute
Federal Building, Room 5A12
Bethesda, MD 20892
Telephone: (301) 496-5911
GENETIC AND METABOLIC FACTORS IN OBESITY
RFA AVAILABLE: 90-HD/DK-05
P.T. 34, AA; K.W. 1002019, 0715135, 0715145, 0403001, 0411005
National Institute of Child Health and Human Development
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date: June 11, 1990
The Endocrinology, Nutrition and Growth Branch of the Center for Research for
Mothers and Children (CRMC) of the National Institute of Child Health and
Human Development (NICHD), and the Obesity, Eating Disorders, and Energy
Regulation Program of the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) invite research grant applications for studies of
genetic and metabolic factors associated with the development of obesity in
childhood, adolescence and adulthood, as well as genetic and metabolic factors
discernible in childhood that predict the onset of obesity later in life. By
issuing this request for applications (RFA), the NICHD and the NIDDK are
encouraging investigators' interest in a research area important to their
mission. Applications are invited from investigators to enter a national
competition for awards anticipated to be made by NICHD/NIDDK in fiscal year
1991.
Research Goals:
The primary focus of this RFA is to identify genetic and metabolic markers in
children, adolescents and adults that predict the development of obesity.
Recent evidence points to a genetic component of variations in energy
expenditure and implies that a tendency to obesity is a consequence of
increased efficiency of energy storage or conservation. Thus, analyses are
needed of the basis for individual differences in energy expenditure for basal
metabolic rate, thermic effect of food and activity. The identification of
genetic components of energy metabolism in childhood could lead to the
development of robust predictors of obesity in certain individuals and
families. The ultimate goal is to discover genetic and metabolic markers of
the pre-obese state in order to identify those individuals at high risk of
becoming obese and to design preventive programs to meet their needs.
Linkage studies of candidate genes contributing to obesity should be performed
in families predisposed to severe obesity and in animal models of hereditary
obesity. Animal models may be useful for intensive metabolic studies of the
pre-obese state in fetal and neonatal life. A search should be made of the
central nervous system and hypothalamic-pituitary axis in these animals for
neurohumoral factors leading to obesity. Differences in the mechanism leading
to the development of obesity, including regional distribution of adipose
tissue among subjects of different age, gender and ethnic origin, are
important to ascertain and may be associated with different biological or
genetic markers.
INCLUSION OF MINORITIES IN STUDY POPULATIONS: Applicants are urged to give
added attention (where feasible and appropriate) to the inclusion of
minorities in study populations for research into the etiology of diseases,
research in behavioral and social sciences, clinical studies of treatment and
treatment outcomes, research on the dynamics of health care and its impact on
disease, and appropriate interventions for disease prevention and health
promotion. If minorities are not included in a given study, a clear rationale
for their exclusion should be provided.
INCLUSION OF FEMALES IN STUDY POPULATIONS: Applicants are urged to consider
the inclusion of females in study populations for all clinical research
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 2
efforts. Exceptions would be studies of diseases which exclusively affect
males or where involvement of pregnant women may expose the fetus to undue
risks. Gender differences should be noted and evaluated. If females are not
to be included, a clear rationale should be provided for their exclusion.
In order to provide more precise information to the treatment community, it is
recommended that publications resulting from research in which the study
population was limited to one sex for any reason other than that the disease
or condition studied exclusively affects that sex, should state, in the
abstract summary, the gender of the population studied, e.g., "male patients,"
"male volunteers," "female patients," "female volunteers."
Mechanism of Support:
Applications in response to this RFA will be funded through the traditional
individual research award programs of the NICHD and the NIDDK. This
announcement is for a single competition with the deadline for receipt of
applications of May 28, 1990. The earliest possible start date for grants
would be April 1, 1991. It is anticipated that eight (8) grants will be
awarded under this program, contingent upon receipt of a sufficient number of
meritorious applications and the availability of funds.
Review Procedures and Criteria:
Applications will be reviewed by NICHD and NIDDK staff for responsiveness to
the RFA. Applications judged to be nonresponsive will be returned. The
applicant may resubmit the application and have it assigned for review in the
same manner as unsolicited grant applications. An application will be
considered nonresponsive to this RFA if it is identical to one already
submitted to the NIH for review, unless the previous application is withdrawn.
Responsive applications may be subjected to a triage by a peer-review group to
determine their scientific merit relative to the other applications received
in response to this RFA. NIH will withdraw from competition those
applications judged to be noncompetitive and notify the applicant and
institutional business official. Those applications judged to be competitive
will be further evaluated for scientific/technical merit by a review convened
solely for this purpose by the Scientific Review Program, NICHD. Criteria for
the initial review include the significance and originality of research goals
and approaches; the feasibility of research and adequacy of the experimental
design; the research experience and competence of the investigator(s) to
conduct the proposed work; the adequacy of investigator effort devoted to the
project; and the appropriateness of the project duration and cost relative to
the work proposed. Following review by the Initial Review Group, applications
will be evaluated by either Institute's Advisory Council for program relevance
and policy issues before awards for meritorious proposals are made.
Application Procedure:
Applications should be submitted on Form PHS 398 (rev. 10/88), available in
business or grants offices at most academic research institutions or from the
Division of Research Grants, NIH. The complete RFA which contains background
information and detailed instructions for application is available on request.
Additional Information:
Gilman D. Grave, M.D. OR Van S. Hubbard, M.D., Ph.D.
Chief, Endocrinology, Nutrition Director
and Growth Branch Obesity, Eating Disorders, and
Center for Research for Mothers Regulation Program
and Children National Institute of Diabetes and
National Institute of Child Health Digestive and Kidney Diseases
and Human Development Westwood Bldg., Room 3A18
Executive Plaza North, Room 637 Bethesda, MD 20892
Bethesda, MD 20892 Telephone: (301) 496-7823
Telephone: (30l) 496-5593
This program is described in the catalog of Federal Domestic Assistance No.
13.865, Research for Mothers and Children. Awards will be made under the
authority of the Public Health Service Act, Section 301 (42 USC241), and
administered under PHS grant policies and Federal Regulations 42 CFR Part 52
and 45 CFR Part 74. This program is not subject to review by a Health Systems
Agency.
This program is described in the catalog of Federal Domestic Assistance No.
13.848, Digestive Diseases and Nutrition. Awards will be made under the
authority of the Public Health Service Act, Title III, Section 301 (Public Law
78-410, as amended; 42 USC 241) and administered under PHS grant policies and
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 3
Federal Regulations most specifically at 42 CFR Part 52 and CFR Part 74; this
Executive Order 12372 or Health Systems Agency review.
NEW APPROACHES TO UNDERSTANDING TRANSFORMATION BY SV40 VIRUS, POLYOMAVIRUSES
AND ADENOVIRUSES
RFA AVAILABLE: 90-CA-09
P.T. 34; K.W. 1002019, 1002045, 0755020, 0785140
National Cancer Institute
Letter of Intent Receipt Date: June 15, 1990
Application Receipt Date: August 24, 1990
INTRODUCTION
Simian virus 40 (SV40), mouse polyomavirus and adenovirus are DNA tumor
viruses that are important model systems in the study of virally induced
tumors in susceptible animals and the transformation of cells in culture. The
primary cause of these neoplastic events is the introduction into cells of
viral transforming genes that encode viral oncoproteins (SV40/polyoma
T-antigens and the adenovirus E1 proteins). The transformation mechanism of
these viruses is unknown, but recent evidence suggests that it is mediated by
interactions with cellular proteins. Support for this model comes from the
discovery of strong binding interactions between the viral oncoproteins and
cellular proto- and anti-oncogene products. The first such association to be
identified was the complex between middle T-antigen of polyomavirus and the
product of the c-src proto-oncogene. More recently, the large T-antigens of
SV40 and polyomavirus and the E1A protein of adenovirus each were shown to
form complexes with the product of the Rb anti-oncogene (the retinoblastoma
tumor suppressor gene). Current research is focused primarily on the
interactions of these viral oncoproteins and cellular genes. However,
cellular transformation is a complex mechanism involving many different
metabolic and regulatory pathways in addition to the cellular processes
associated with the Rb, p53 and c-src proteins. The goal of this Request for
Applications (RFA) is to stimulate research on the interaction of viral
oncoproteins with other cellular proteins that also may play a role in
transformation.
The present RFA is for a single competition with deadlines of August 24, 1990
for receipt of applications and June 15, 1990 for receipt of letters of
intent.
RESEARCH GOALS AND SCOPE
The major goal of this RFA is to stimulate research leading to an
understanding of SV40, polyomavirus, and adenovirus transformation of cells in
terms of the cellular processes which are altered by viral oncoproteins. The
scope of this RFA includes studies of SV40, polyomaviruses (including BK virus
and JC virus) and adenoviruses. Functional studies of viral
oncoprotein-cellular protein complexes will be encouraged. Studies on the Rb,
p53, and c-src interactions with oncoproteins should not be the focus of the
proposed studies since they are already being extensively studied.
(Applications focusing only on these will be considered unresponsive to the
RFA and returned to investigators.). Where appropriate, some experiments
dealing with these cellular proteins may be included for comparisons or to
extend mechanistic ideas involving several cellular proteins. Examples of the
research objectives (which are not all inclusive) that may be supported under
this RFA are: 1) investigations of the impact of viral oncoprotein/cellular
protein complexes on elements of cellular regulation related to transformation
such as (but not limited to) second messenger regulation, cell cycle control,
transactivation of cellular protein synthesis, and alteration of plasma
membrane properties (e.g., contact inhibition); 2) development and application
of new approaches to understand the regulatory activities of pertinent
cellular proteins and second messenger molecules and assessment of the role of
these processes in cellular transformation; 3) functional and structural
characterization of cellular proteins that bind to viral oncoproteins; 4)
development and application of new techniques and reagents to identify and
characterize additional cellular proteins that bind to viral oncoproteins.
Where appropriate, collaborative arrangements to facilitate the achievement of
research goals should be considered.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 4
MECHANISM OF SUPPORT
This RFA will use the traditional National Institutes of Health (NIH) research
project (RO1). Responsibility for the planning, direction and execution of
the proposed project will be solely that of the applicant. Except as stated
in this RFA, awards will be administered under PHS grants policy as stated in
the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987.
Approximately $750,000 in total costs per year for five (5) years will be
committed to specifically fund applications which are submitted in response to
this RFA. The funding level is dependent on the receipt of a sufficient
number of applications of high scientific merit. The total project period for
applications submitted in response to the present RFA should not exceed five
(5) years. The earliest feasible start date for the initial awards will be
April 1, 1991. Although this program is provided for in the financial plans
of the National Cancer Institute (NCI), award of grants pursuant to this RFA
is also contingent upon the availability of funds for this purpose.
Non-profit and for-profit institutions, and foreign as well as domestic
institutions, are eligible to apply.
This RFA is a one-time solicitation. Generally future unsolicited competing
renewal applications will compete as research project applications with all
other investigator-initiated applications and be reviewed in a standing
Division of Research Grants study section. However, should the NCI determine
that there is a sufficient continuing program need, NCI may announce a request
for renewal applications.
INQUIRIES
Written or telephone inquiries concerning the objectives and scope of this RFA
or about whether or not specific proposed research would be responsive are
encouraged and should be directed to Dr. Susan B. Spring at the address below.
The program director welcomes the opportunity to clarify any issues or
questions from potential applicants.
Dr. Susan B. Spring
Program Director
DNA Virus Studies I
Biological Carcinogenesis Branch
Division of Cancer Etiology
National Cancer Institute
Executive Plaza North, Room 540
Bethesda, MD 20892
Telephone: (301) 496-4533
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTION PROJECTS
RFA AVAILABLE: OD-90-01
P.T. 34; K.W. 1014002, 1014006
National Institutes of Health
Letter of Intent Receipt Date: March 23, 1990
Application Receipt Date: May 7, 1990
BACKGROUND INFORMATION
The Congress has recently addressed the issue of extramural research
facilities construction through the Fiscal Year 1990 appropriations process.
The DHHS Appropriations Act for Fiscal Year 1990, Public Law 101-166, states
in part that the Secretary shall transfer $14,800,000 from "appropriations
available to each of the Institutes which shall be available for extramural
facilities construction grants if authorized in law and if awarded
competitively including such amount as he may deem appropriate for research
animal production facilities." As stated, the appropriations are available
for grant awards under current construction grant authority. Conference
language accompanying the Appropriations Act further states that such
construction projects be "identified by the Director of NIH as being of urgent
national importance." In addition, the conference language states, "The
conferees have deleted the earmarks for seven extramural construction projects
as proposed by the Senate without prejudice. The conferees believe that these
are meritorious projects which should be well received in the normal
competitive process." Subsequently, with enactment of Public Law 101-190, the
National Institutes of Health (NIH) is authorized to award a contract to "a
public or nonprofit, private entity for constructing facilities for the
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 5
purpose of the development and breeding of specialized strains of mice
(including inbred and mutant mice) for use in biomedical research." The NIH
intends to award a grant for this purpose either under its existing authority,
or pursuant to an amendment of Public Law 101-190 to authorize a grant award.
Given the breadth of activities that may be appropriate for support in
response to these Congressional actions, the National Institutes of Health is
issuing two concurrent Requests for Applications (RFA's) to solicit
construction proposals. RFA Number OD-90-01 will be limited to applications
for the construction of facilities for biomedical research and/or services to
support such research (which may include a laboratory animal production
component); RFA Number OD-90-02 will be limited to applications for
construction of a large-scale, specialized, mouse production facility. The
main objective of each is to facilitate the conduct of biomedical research by
providing funds for construction of new facilities and for the purchase of
fixed equipment essential for the operation of these facilities.
The purpose of this RFA is to invite grant applications for the construction
of research/research support facilities.
OBJECTIVES AND SCOPE
Support may be requested for the construction of new facilities and additions
or renovations to existing facilities to meet the biomedical research or
biomedical research support needs of an institution, or of a research group at
that institution or elsewhere that utilizes the resources of that institution.
The purpose of the proposed facility must be within the scope of one of the
statutes authorizing the awards. Those statutes authorize construction grants
which would benefit the fields of cancer, vision and heart, lung and blood
research. Associated fixed equipment necessary for operation of these
facilities may also be requested as part of the application.
MECHANISM OF SUPPORT
Any domestic non-Federal institution, organization, or association which
conducts or supports biomedical research is eligible to apply. Construction
grant applications from non-Federal institutions, organizations, or
associations, previously submitted to and peer-reviewed by NIH but which
currently remain unfunded, will automatically be considered under this RFA
without the submission of a new application if they are responsive to the
objectives described above. Up to $2,000,000 of the $4,800,000 available
under this RFA has been identified for funding of the highest rated of the
applications in this category. The remainder of these applications will be
considered along with the applications submitted in response to this RFA.
However, if the design or plans for construction differ markedly from that
which was peer-reviewed, a new application will be required. These applicants
are strongly encouraged to request a copy of the complete RFA and special
instructions for completion of the application to determine their need to
submit additional assurances and certifications, as well as other information
they may feel relevant to their proposal in relation to the RFA.
NIH staff will verify application and award eligibility. Those judged to be
unresponsive or ineligible will be returned to the investigator.
The award mechanism will be the construction grant award. Awards will be
administered under Federal Regulation 42 CFR Part 74 - Administration of
Grants, and for cancer construction projects, 42 CFR Part 52b. Organizations
operated for profit are directed to 45 CFR 74.710 for guidance regarding title
to real property and equipment acquired under this program.
This one-time solicitation based on the Fiscal Year 1990 appropriation will
make available $2,800,000 for this initiative. Up to 75 percent of the
allowable costs of a project may be provided, not to exceed $2,800,000. Prior
to a grant award, the applicant must provide an assurance of required matching
funds and that other funds have been secured to meet any projected costs in
excess of the award amount. Requests of less than $500,000 will not be
accepted. No indirect costs or continuation costs will be awarded.
For additional information and a copy of the complete RFA and application
Standard Form 424 materials, please contact:
Mr. Kenneth Brow
Chief, Research Facilities Branch
Division of Cancer Biology and Diagnosis
National Cancer Institute
Executive Plaza North, Room 300
Bethesda, MD 20892
Telephone: (301) 496-8534
NIH GUIDE - Vol. 19, No. 7, february 16, 1990 - Page 6
Grants for research facilities construction programs of the National
Institutes of Health are subject to Executive Order 12372. Awards will be
made under the construction grant authorities in the Public Health Service
Act, Sections 413(b)6(B), 421(b)(2)(B), and 455, and administered under PHS
grant policies and Federal Regulations 45 CFR Part 74 and 42 CFR Part 52b for
cancer construction only. This program is described in the Catalog of Federal
Domestic Assistance, Number 13.392, Cancer-Construction.
CONSTRUCTION OF A MOUSE PRODUCTION FACILITY
RFA AVAILABLE: OD-90-02
P.T. 34; K.W. 1002002, 1014002, 1014006
National Institutes of Health
Letter of Intent Receipt Date: March 23, 1990
Application Receipt Date: May 7, 1990
BACKGROUND INFORMATION
The Congress has recently addressed the issue of extramural research
facilities construction through the Fiscal Year 1990 appropriations process.
The DHHS Appropriations Act for Fiscal Year 1990, Public Law 101-166, states
in part that the Secretary shall transfer $14,800,000 from "appropriations
available to each of the Institutes which shall be available for extramural
facilities construction grants if authorized in law and if awarded
competitively including such amount as he may deem appropriate for research
animal production facilities." Conference language accompanying the
Appropriations Act further states that such construction projects be
"identified by the Director of NIH as being of urgent national importance."
In addition, the conference language states, "The conferees have deleted the
earmarks for seven extramural construction projects as proposed by the Senate
without prejudice. The conferees believe that these are meritorious projects
which should be well received in the normal competitive process."
Subsequently, with enactment of Public Law 101-190, the National Institutes of
Health (NIH) is authorized to award a contract to "a public or nonprofit,
private entity for constructing facilities for the purpose of the development
and breeding of specialized strains of mice (including inbred and mutant mice)
for use in biomedical research." The NIH intends to award a grant for this
purpose either under its existing authority or pursuant to an amendment of
Public Law 101-190 to authorize a grant award.
Given the breadth of activities that may be appropriate for support in
response to these Congressional actions, NIH is issuing two concurrent
Requests for Applications (RFA's) to solicit construction proposals. RFA
Number OD-90-01 will be limited to applications for the construction of
facilities for biomedical research and/or services to support such research
(which may include a laboratory animal production component); RFA Number
OD-90-02 will be limited to applications for construction of a large-scale,
specialized, mouse production facility. The main objective of each is to
facilitate the conduct of biomedical research by providing funds for
construction of new facilities and for the purchase of fixed equipment
essential for the operation of these facilities.
The purpose of this RFA is to invite grant applications for the construction
of a mouse production facility.
OBJECTIVES AND SCOPE
Support may be requested for the construction of new facilities and additions
or renovations to existing facilities which will be dedicated to the breeding
and production of specialized strains of mice, including inbred and mutant
mice, necessary to meet the nation's needs in conducting biomedical research
on a broad range of topics. Associated fixed equipment necessary for
operation of these facilities may also be requested as part of the
application.
MECHANISM OF SUPPORT
Any domestic non-Federal public or non-profit private institution,
organization, or association which conducts or supports biomedical research is
eligible to apply.
NIH staff will verify application and award eligibility. Those judged to be
unresponsive or ineligible will be returned to the investigator.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 7
The award mechanism will be the construction grant award. Awards will be
administered under Federal Regulation 45 CFR Part 74 - Administration of
Grants, and for cancer construction projects 42 CFR Part 52b.
This one-time solicitation based on the Fiscal Year 1990 appropriation will
make available $10,000,000 for this initiative. Final amount to be determined
based on the peer-review evaluation. Up to 75 percent of the allowable costs
of a project may be provided, not to exceed $10,000,000. Prior to a grant
award, the applicant must provide an assurance of required matching funds and
that other funds have been secured to meet any projected costs in excess of
the award amount. Requests of less than $500,000 will not be accepted. No
indirect costs or continuation costs will be awarded.
For additional information and a copy of the complete RFA and application
Standard Form 424 materials, please contact:
Mr. Kenneth Brow
Chief, Research Facilities Branch
Division of Cancer Biology and Diagnosis
National Cancer Institute
Executive Plaza North, Room 300
Bethesda, MD 20892
Telephone: (301) 496-8534
Grants for research facilities construction programs of the National
Institutes of Health are subject to Executive Order 12372. All awards will be
made either under the authority of the Public Health Service Act, Title IV,
Section 413(b)6(A) as amended by Public Law 99-158 (42 USC 285a-2) and
administered under PHS grant policies and Federal Regulations 42 CFR Part 52b
and 45 CFR Part 74, or under the authority of an appropriation amendment of
Public Law 101-190 to authorize a grant award. This program is described in
the Catalog of Federal Domestic Assistance, Number 13.392,
Cancer-Construction.
ONGOING PROGRAM ANNOUNCEMENTS
SMALL GRANTS PROGRAM
P.T. 34; K.W. 0755018, 0755015, 0403004
National Heart, Lung, and Blood Institute
I. INTRODUCTION
The National Heart, Lung, and Blood Institute (NHLBI) supports an extensive
portfolio of clinical trial, population research, and demonstration and
education studies that result in gathering large amounts of data essential to
the specific aims of the original project. Often, these types of studies
present unique opportunities to look at unusual or unanticipated outcomes. At
present, there is no mechanism specifically targeted for the analyses of data
not originally documented in the specific aims of the proposal. Therefore,
the NHLBI is instituting a small grant program to allow investigators the
opportunity to analyze areas of interest from readily available data bases.
II. PURPOSE
The NHLBI Small Grant Program is intended to provide limited support for
meritorious research projects to support extended analyses of research data
generated by clinical trial, population research, and demonstration and
education studies.
III. MECHANISM OF SUPPORT
The mechanism of support will be the NIH small grant (RO3). Responsibility
for the planning, direction, and execution of the proposed research will be
solely that of the applicant. Except as otherwise stated in this
announcement, awards will be administered under PHS grants policy as stated in
the Public Health Service Grants Policy Statement, DHHS Publication No. (OASH)
82-50,000, revised January l, l987.
The small grant (R03) mechanism provides research support specifically limited
in time and amount for studies in categorical program areas. Small grants
provide flexibility for initiating studies, which are generally for short-term
projects and are non-renewable. Furthermore, the time interval from
application to funding is shortened under the R03 mechanism, thus allowing new
ideas to be investigated or pursued in a more expeditious manner.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 8
IV. TERMS AND CONDITIONS OF THE AWARD
The proposed project may be related to, but the aims must be distinctly
different from those of pending grant applications or funded research
projects. The request may not be used to supplement projects currently
supported by Federal or non-Federal funds, or to provide interim support for
projects under review by the Public Health Service.
Applicants may request up to $50,000 (direct costs) per year for a 2-year
grant period for technical assistance, supplies, and small equipment required
by the project. Compensation for the principal investigator may be requested
only with strong justification.
V. ELIGIBILITY
Domestic non-profit and for-profit institutions are eligible to apply.
Foreign institutions are ineligible. This award is appropriate for all
investigators who document that they have access to, and demonstrate that they
understand the data necessary to meet the specific aims and objectives of the
proposed project.
VI. REVIEW PROCEDURES AND CRITERIA
A. Review Procedures
Upon receipt, applications will be evaluated by NHLBI staff to determine
whether they are responsive to the program requirements and criteria stated in
this announcement. Applications that are judged non-responsive will be
returned to the applicant. Questions concerning the responsiveness of the
proposed research should be directed to staff as described in Section VIII.
A review committee convened by the Division of Extramural Affairs, NHLBI, will
conduct the initial scientific merit review of applications submitted in
response to this announcement. Second level review will be conducted by NHLBI
senior program staff.
B. Review Criteria
The factors to be considered in the evaluation of each application will be
similar to those used in the review of traditional research project grant
applications. The major factors to be considered in the evaluation of
application will include:
1. The scientific merit of the proposed project, including the originality and
feasibility of the approach, and the adequacy of the experimental design;
2. The competence of the investigator(s) to accomplish the proposed research
goals, and the effort that they will devote to the project;
3. The adequacy of facilities for performance of the proposed research;
4. Documentation that the principal investigator will have access to the data
to be analyzed.
5. Demonstration that the investigator(s) have an understanding of the extent
and limits of the original data base, and how it may affect the proposed
research.
VII. METHOD OF APPLYING
The research grant application form PHS 398 (revised l0/88) must be used in
applying for these grants. These forms are available at most institutional
business offices, or from the Office of Grant Inquiries, Division of Research
Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda,
MD 20892.
Please refer to the supplemental instructions at the end of this announcement
when completing the application. In addition, it is important to include with
the application, written documentation that the data to be examined will be
available to the principal investigator.
Send or deliver the original and FOUR, signed exact photocopies in one package
to the Division of Research Grants, using the mailing label enclosed in the
application kit, as specified in the General Instructions.
In order to expedite the review of the application, mail or deliver TWO
additional exact photocopies of the signed application to:
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 9
Chief,
Contracts, Clinical Trials and Training Review Section
Review Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 548
Bethesda, MD 20892
The review schedule is planned as follows:
Application Initial Review Earliest Possible
Receipt Date Funding Date
October 1 Feb/Mar May
February 1 May/June August
June 1 Oct/Nov January
VIII. STAFF CONTACTS
For further information regarding the scientific review, prospective
applicants should contact the Chief, Contracts, Clinical Trials and Training
Review Section, Review Branch, Division of Extramural Affairs, National Heart,
Lung, and Blood Institute, at the address listed above.
For inquiries about the programmatic aspects of this announcement, applicants
should contact:
Director
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Federal Building, Room 4l6
Bethesda, MD 20892
Director
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Federal Building, Room 2l2
Bethesda, MD 20892
Director
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 6Al6
Bethesda, MD 20892
Charles Hollingsworth, Dr. P.H.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 5l8
Bethesda, MD 20892
The programs of the Institute are described in the Catalog of Federal Domestic
Assistance No. 13.837, Heart and Vascular Diseases; No. 13.838, Lung Diseases;
and No. 13.839, Blood Diseases and Resources. Awards will be made under
authority of the Public Health Service Act, Title IV, Section 421(b)(2)(B)
(Public Law 99-158; 42 USC 241), and administered under PHS grant policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review.
SUPPLEMENTAL INSTRUCTIONS FOR THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
SMALL GRANTS PROGRAM
Applications are to be submitted on the standard PHS research grant
application form PHS-398, Rev. l0/88, following the instructions supplied with
those forms EXCEPT for the items listed below (See pages 12-23, Instructions
Sheet for PHS-389):
SECTION l.
l. Face page of application:
Item 2: Mark "YES" and enter: Small Grants Program, NHLBI;
Item 6: A maximum of 2 years of support may be requested;
Item l0: Not applicable; Mark N/A.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 10
2. Application page 4 and 5:
Detailed budget for the first and second year must be limited to the following
categories: personnel (technical assistance), supplies, and small equipment
items. The total award request for a 2-year period may not exceed a maximum
of $l00,000 direct costs, or $50,000 direct costs per year.
3. Biographical data:
Not to exceed one page for principal investigator. List most important
positions and relevant publications.
SECTION 2.
l. Introduction: Use only for revised or amended applications. Otherwise,
not applicable.
2. Research Plan:
A. Specific Aims: Not to exceed one-half page.
B. Background and Significance: Not to exceed one page.
C. Progress Report/Preliminary Studies: A progress report is not applicable.
If data from preliminary studies are available, the report should not exceed
one-half page.
D. Experimental Design and Methods: Not to exceed three pages.
E. Consortium/Contractual Arrangements: Not to exceed one-half page.
F. Literature Cited: Not to exceed one page.
NINTH ANNOUNCEMENT - TRANSFUSION MEDICINE ACADEMIC AWARD
P.T. 34; K.W. 0750010, 0710030, 0785035
National Heart, Lung, and Blood Institute
Application Receipt Date: November 20, 1990
The Transfusion Medicine Academic Award (TMAA) was initiated in January 1983,
to: (1) stimulate the development of multidisciplinary curricula in
transfusion medicine, and (2) permit the awardee to broaden his or her
expertise in transfusion medicine so as to contribute more effectively to the
teaching, research, and clinical needs of this discipline. "Transfusion
Medicine" is defined as a multidisciplinary area concerned with the proper use
or removal of blood and its components in the treatment or prevention of
disease states. Schools of medicine, osteopathy, or veterinary medicine
(United States or its possessions and territories), singly or in concert, are
eligible to apply for one 5-year TMAA (nonrenewable), providing they possess
the requisite blood bank, patient care, and research facilities required for
such an activity. In the case of veterinary medicine, the focus of the
program must be on its applicability to human health and disease and requires
a demonstrated collaborative program between schools of animal and human
medicine. The TMAA may provide salary, fringe benefits, and supporting costs
of up to $85,000 annually to faculty members who are established
investigators, and skilled organizers and negotiators. The number of awards
will depend on the availability of funds. MINORITY MEDICAL SCHOOLS ARE
ENCOURAGED TO APPLY.
THIS IS THE NINTH AND FINAL ANNOUNCEMENT FOR TRANSFUSION MEDICINE ACADEMIC
AWARDS.
The Transfusion Medicine Academic Award encourages the development of teaching
and research programs in transfusion medicine. Teaching, research, and
clinical responsibilities in transfusion medicine usually have not been
coordinated into a definable program but are dispersed among basic and
clinical science disciplines and among activities of the local transfusion
services or blood center facility. It is important to note that a transfusion
medicine curriculum may not require additional curriculum time; existing
course time and teaching materials, as components of other disciplines, may be
coordinated into an overall program and organized to focus on emerging and
important areas of transfusion medicine. Some schools may find it desirable
to assemble the appropriate components into a specific unit. Others may wish
to retain the transfusion medicine discipline as part of another major
department.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 11
This award is also intended to:
o attract to the field of transfusion medicine outstanding students
and promising young clinicians and scientists who can serve in the
teaching, research, and clinical aspects of transfusion medicine;
o encourage the development of faculty capable of providing
appropriate instruction in the field of transfusion medicine;
o facilitate interchange of information, and evaluation and
educational techniques among research, medical, and blood service
communities; and
o enable the grantee institution to develop a continuing transfusion
medicine program, using local support, when this Award terminates.
Requests for the TMAA Program Guidelines should be directed to:
Fann Harding, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 5A08
Bethesda, MD 20892
Telephone: (301) 496-1817
The programs of the Division of Blood Diseases and Resources of the National
Heart, Lung, and Blood Institute are identified in the Catalog of Federal
Domestic Assistance, number 13.839. Awards will be made under the authority
of the Public Health Service Act, Section 301 (42 USC 241) and administered
under PHS grant policies and Federal regulations, most specifically 42 CFR
Part 52 and 45 CFR Part 74. This program is not subject to the
intergovernmental review requirements of Executive Order 12372, or to Health
Systems Agency Review.
COMPREHENSIVE PREVENTION RESEARCH IN DRUG ABUSE
P.T. 34; K.W. 0404009, 0745027, 0404000, 0403004
National Institute on Drug Abuse
PURPOSE
The purpose of this announcement is to encourage rigorous scientific study of
multiple component substance abuse prevention technologies implemented across
several social systems including schools, families, the peer group, the
workplace, and residential neighborhoods to determine their efficacy in
preventing the onset of drug use and progression to abuse. Studies should
involve the use of randomized controlled clinical trials or well-controlled
quasi-experimental research designs. A secondary goal of the research is the
development of psychometrically-sound measures, instruments and data
collection procedures to assess the process, outcome, and impact of
comprehensive prevention strategies. Special attention should be given to
populations at high risk of drug use onset and progression, particularly those
living in communities threatened by drug distribution activities. Research
should focus upon a broad spectrum of drug behaviors, such as the use of
tobacco products, marijuana, cocaine/crack, methamphetamines, and the
prevention of polydrug use/abuse.
RESEARCH OBJECTIVES
Epidemiologic research over the last ten years indicates a significant
decrease in the use of marijuana and, more recently, a decline in the use of
cocaine. Analyses of these data suggest that changes in drug use occurred
because of an increased perception of the harmful consequences of drug use and
abuse and personal and social disapproval of the use of illict substances.
Controlled intervention research indicates that comprehensive drug prevention
programs can prevent the incidence and reduce the prevalence of the use of
cigarettes, alcohol, marijuana, and cocaine for adolescents exposed to
comprehensive prevention programs in comparison to those youth not receiving
these interventions. Comprehensive drug abuse prevention includes systematic
implementation of multiple components to include: effective use of the media;
drug education and intervention in the schools and workplace; parent education
and formation of self-help groups; development of community coalitions to
combat drug abuse and drug distribution; and enactment and enforcement of
salient anti-drug policies within schools, the workplace, and communities.
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 12
Research on the efficacy and effectiveness of comprehensive drug prevention
programs is needed in two general areas: 1) to assess the long-term effects
of comprehensive drug prevention, and 2) to determine the generalizability of
these research findings to high-risk populations. Research focused upon the
individual, the social/physical environment, and communities is required.
Relevant to the individual, research indicates that a promising approach to
drug prevention would be one that promotes self-regulated health behavior
change. Intervention research is needed to test strategies that enhance the
vital role played by family, peers, neighbors, teachers, and others to
encourage and reinforce this process. Finally, research is needed to test
drug preventive interventions that involve community organizations and
institutions to establish an environment in which durable, positive
self-regulated behavior change can be developed and maintained. This program
will also support research to further develop and test process, outcome, and
impact evaluation research techniques appropriate for comprehensive drug
prevention programs.
It is recommended that research applications submitted under this grant
announcement focus initially upon pre-adolescence through early adulthood.
However, an applicant may propose expanding the research to include additional
stages of the life span during later phases of the same study or planned for
subsequent, related research. Proposed studies must directly assess program
and research questions pertinent to subpopulations and communities that may be
at high risk to drug use/abuse and related problems.
INCLUSION OF MINORITIES IN STUDY POPULATIONS
Applicants are urged to give added attention (where feasible and appropriate)
to the inclusion of minorities in study populations for research into the
etiology of diseases, research in behavioral and social sciences, clinical
studies of treatment and treatment outcomes, research on the dynamics of
health care and its impact on disease, and appropriate interventions for
disease prevention and health promotion. If minorities are not included in a
given study, a clear rationale for their exclusion should be provided.
INCLUSION OF FEMALES IN STUDY POPULATIONS
Applicants are urged to consider the inclusion of females in study populations
for all clinical research efforts. Exceptions would be studies of diseases
which exclusively affect males or where involvement of pregnant women may
expose the fetus to undue risks. Gender differences should be noted and
evaluated. If females are not to be included, a clear rationale should be
provided for their exclusion.
In order to provide more precise information to the treatment community, it is
recommended that publications resulting from research in which the study
population was limited to one sex for any reason other than that the disease
or condition studied exclusively affects that sex, should state, in the
abstract summary, the gender of the population studied, e.g., "male patients,"
"male volunteers," "female patients," "female volunteers."
MECHANISM OF SUPPORT
Support mechanisms include: Research Projects (R01), and Program Projects
(P01).
ELIGIBILITY
Applications may be submitted by public or private nonprofit or for-profit
organizations such as universities, colleges, hospitals, laboratories, units
of State or local governments, and eligible agencies of the Federal
government. Women and minority investigators are encouraged to apply.
Applications are especially encouraged from State governments with research
units and/or State governments collaborating with university-based research
units.
APPLICATION PROCEDURES
Applicants should use the research grant application form PHS 398 (Rev.
10/88). The title of this announcement "COMPREHENSIVE PREVENTION RESEARCH IN
DRUG ABUSE" should be typed in item number 2 on the face page of the PHS 398
application form and check the YES box.
Application kits containing the necessary forms and instructions may be
obtained from business offices or offices of sponsored research at most
universities, colleges, medical schools, and other major research facilities.
If such a source is not available the following office may be contacted for
the necessary application material and a copy of the announcement:
NIH GUIDE - Vol. 19, No. 7, February 16, 1990 - Page 13
Grants Management Branch
National Institute on Drug Abuse
5600 Fishers Lane, Room 8A-54
Rockville, MD 20857
Telephone: (301) 443-6710
RECEIPT AND REVIEW SCHEDULE
Receipt Initial Advisory Earliest
Date Review Council Start Date
April 9, 1990 June/July Sept. 1990 Sept. 1990
Thereafter, the following application receipt dates and review schedule will
apply. Applications received after April 9, 1990, will be reviewed in the
next appropriate review schedule, as indicated below.
Receipt Initial Advisory Earliest
Date Review Council Start Date
Feb. 1/Mar.1* June/July Sept./Oct. Dec. 1
June 1/July 1* Oct./Nov. Jan./Feb. April 1
Oct. 1/Nov. 1* Feb./Mar. May/June July 1
*Amended applications (new or renewal) are to be submitted on these dates
apply for RO1s only.
Consequences of Late Submission: Applications received after the above
receipt dates are subject to the next review cycle or may be returned to the
applicant.
REVIEW PROCESS AND CRITERIA
The Division of Research Grants, NIH, serves as a central point for receipt of
applications for most discretionary PHS grant programs. Applications received
under this announcement will be assigned to an Initial Review Group (IRG) in
accordance with established PHS Referral Guidelines. Criteria for
scientific/technical merit review of applications will include the following:
significance and originality from a scientific or technical standpoint of the
goals of the proposed research; adequacy of the methodology proposed to carry
out the research; feasibility of the proposed research; qualifications and
research experience of the principal investigator and other key personnel;
availability of adequate facilities, other resources, and collaborative
arrangements necessary for the research; appropriateness of budget estimates
for the proposed research activities; and adequacy of provisions for the
protection of human subjects, as applicable.
AWARD CRITERIA
Applications recommended for approval by an appropriate National Advisory
Council will be considered for funding on the basis of overall scientific,
clinical and technical merit of the proposal as determined by peer review,
appropriateness of budget estimates, program needs and balance, policy
considerations, adequacy of provisions for the protection of human subjects,
and availability of funds.
INQUIRIES
Further information and consultation on program requirements relevant to
prevention/intervention research can be obtained from:
Dr. William Bukoski
Program Director and Acting Chief, Intervention Section
National Institute on Drug Abuse
5600 Fishers Lane, Room 10-A-20
Rockville, MD 20857
Telephone: (301) 443-1514
This program is described in the Catalog of Federal Domestic Assistance No.
13.279. Grants will be awarded under the authority of sections 301 and 515 of
the Public Health Service Act (42 USC 241 and 290cc).
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD
BUILDING IS: 5333 Westbard Avenue, Bethesda, MD 20816